Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
BMEA Catalyst Timeline
Dated clinical, regulatory and corporate events for Biomea Fusion, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Biomea Fusion, Inc.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How BMEA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-16 | BMF-650 | Phase 1 data presentation | Phase 1 |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| icovamenib Small MoleculesNCT07502495 | Type 2 Diabetes | Phase 2 | ACTIVE NOT_RECRUITING | 124 | Sep 1, 2027 | ||||||
| BMF-219 Small MoleculesCompletedNCT05731544 | Type 2 Diabetes Mellitus | Phase 1/2 | COMPLETED | 443 | Jul 8, 2025 | ||||||
| BMF-219 Small MoleculesCompletedNCT06152042 | Type 1 Diabetes Mellitus | Phase 2 | COMPLETED | 37 | Jul 18, 2025 | ||||||
| BMF-500 Small MoleculesCompletedNCT05918692 | Acute Myeloid Leukemia | Phase 1 | COMPLETED | 35 | Apr 30, 2026 | ||||||
| BMF-650 Small MoleculesCompletedNCT07223216 | Obesity | Phase 1 | COMPLETED | 90 | Aug 26, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every BMEA program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Erdtmann Rainer MDirector, Officer (See Remarks) | Grant/Award | 452,512 452,512 held | $0.00 | 04/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BMEA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 0.1 % (-50 %) | 5.63 M | 1.45 M | -31.15% ( -656.96 K) |
Ownership Trends
BMEA Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How BMEA ranks across every disease it competes in
BMEA News
Biomea Fusion to Participate in Upcoming Investor Conferences
Biomea Fusion will participate in several upcoming investor conferences, including the Jefferies Global Healthcare Conference and Citi's 2026 Global Healthcare Conference. Management will engage in fireside chats and one-on-one meetings to discuss their clinical-stage biopharmaceutical developments. The company focuses on therapies for diabetes and obesity.
Read more →Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights
Biomea Fusion reported its third quarter 2026 results, highlighting the completion of enrollment in the Phase II COVALENT-211 trial for icovamenib. The company also announced positive Phase I results for BMF-650, which demonstrated weight reduction. Additionally, the cash runway is projected to last into the second quarter of 2027, supporting ongoing clinical trials.
Read more →Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek® 2026
Biomea Fusion announced it will present Phase 1 results for BMF-650, an oral GLP-1 receptor agonist, at ObesityWeek 2026. The conference is scheduled for November 14-17, 2026, in National Harbor, Maryland. The presentation will be led by Dr. Thorsten A. Kirschberg on November 16, 2026.
Read more →Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
Biomea Fusion announced positive Phase 1 results for BMF-650, an oral GLP-1 receptor agonist. The trial showed consistent weight reduction of 1.5% to 3.2% across cohorts, with no severe adverse events. The drug demonstrated good tolerability, even at higher doses, supporting further evaluation. The company plans to continue development and explore strategic partnerships.
Read more →Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
Biomea Fusion, Inc. will announce results from its Phase I clinical study of BMF-650, a next-generation oral small-molecule GLP-1 receptor agonist, on October 13, 2026. The company aims to address diabetes and obesity, significant global health challenges. A conference call will follow the announcement to discuss the results.
Read more →Biomea Fusion Announces Termination of Proposed Public Offering of Securities
Biomea Fusion has announced the termination of its proposed public offering of securities due to unfavorable market conditions. The decision was made to protect the interests of the company's stockholders. No securities were sold in connection with the offering, which was initially announced on September 22, 2026.
Read more →Biomea Fusion Announces Proposed Public Offering of Securities
Biomea Fusion has announced a proposed public offering of its common stock and pre-funded warrants. The offering is subject to market conditions and includes a 30-day option for underwriters to purchase additional shares. The company focuses on developing therapies for diabetes and obesity, aiming to provide transformative treatments. However, uncertainties regarding the offering's completion and terms are noted.
Read more →Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
Biomea Fusion has completed enrollment in the COVALENT-211 Phase II trial, evaluating icovamenib for insulin-deficient Type 2 Diabetes patients. The trial enrolled 64 participants and aims to assess glycemic control over a 52-week period. Topline results for the primary endpoint are anticipated in the first quarter of 2027, following promising data from earlier studies.
Read more →Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
Biomea Fusion has initiated a new arm of its OPAL study, dosing the first participant with icovamenib combined with low-dose semaglutide. This study aims to evaluate the effects of this combination on weight loss and various health metrics in individuals who are overweight or obese. The trial will assess whether icovamenib can enhance the efficacy of semaglutide, focusing on broader metabolic health outcomes.
Read more →Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
Biomea Fusion reported its second quarter 2026 financial results, highlighting ongoing enrollment in two Phase II trials for Type 2 diabetes and a Phase I trial for obesity. The company anticipates initial weight reduction data from its BMF-650 trial in Q3 2026. Financially, Biomea reported a net loss of $8.3 million but has a cash runway extending into Q2 2027.
Read more →Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
Biomea Fusion presented promising new clinical and translational data for icovamenib at the ADA 86th Scientific Sessions. The data highlights potential benefits in muscle preservation, fat reduction, and improvements in glycemic control among type 1 and type 2 diabetes patients. Additionally, Biomea announced the expansion of its Phase I BMF-650 study to optimize dosing and enhance weight loss potential. Overall, the findings support icovamenib's broader therapeutic utility in obesity and diabetes management.
Read more →Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
Biomea Fusion has announced a collaboration with the University of Leicester to evaluate the effects of icovamenib in combination with semaglutide on obesity. This study, part of the OPAL platform trial, aims to assess improvements in physical function and metabolic outcomes. The trial will begin enrollment in Q3 2026, focusing on individuals who are overweight or obese without type 2 diabetes.
Read more →Biomea Fusion to Participate at Upcoming Investor Conferences - May 12, 2026
Biomea Fusion, Inc. announced its participation in upcoming investor conferences, highlighting its focus on developing therapies for diabetes and obesity. The company aims to address metabolic disorders affecting a large portion of the global population. Webcasts of the events will be available for those unable to attend live.
Read more →Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
Biomea Fusion reported its first quarter 2026 financial results, highlighting progress in its clinical trials for icovamenib in type 1 and type 2 diabetes. The company successfully completed chronic toxicology studies and initiated two Phase II trials for type 2 diabetes. Additionally, topline data from the Phase II COVALENT-112 trial showed promising results, with a cash runway projected into early 2027.
Read more →Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
Biomea Fusion announced that three abstracts on icovamenib will be presented at the ADA 86th Scientific Sessions. The presentations will showcase data on the investigational oral menin inhibitor's effects on beta cell function in type 1 and type 2 diabetes. The event will take place from June 5-8, 2026, in New Orleans.
Read more →COVALENT-112 Topline Results BIOMEA
Biomea Fusion, Inc. has shared forward-looking statements regarding future business and financial performance. The presentation emphasizes the uncertain nature of these predictions, which are influenced by various risks, including regulatory approvals and market dynamics. Specifically, the discussion touches on the investigational therapies for Type 1 Diabetes and the limitations associated with existing treatment options. A focus is placed on the anticipated clinical trials and the goals of restoring beta cell function, although challenges persist in achieving durable therapeutic outcomes.
Read more →Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
Biomea Fusion announced positive results from its Phase 2 COVALENT-112 trial, showing a 52% increase in mean C-peptide AUC at Week 12 for patients with type 1 diabetes treated with icovamenib. The treatment effects were durable, with only a 7% decline in C-peptide levels observed at Week 52. Icovamenib was well tolerated, and the company plans to advance its type 1 diabetes program further.
Read more →Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
Biomea Fusion has announced the dosing of its first patient in the Phase II clinical programs, COVALENT-211 and COVALENT-212, which target type 2 diabetes patients not achieving glycemic control with standard therapies. These studies assess the investigational drug icovamenib, anticipated to deliver topline data by the end of 2026. The trials focus on patients requiring improved glucose management, demonstrating previously observed durability in response. This marks a critical advancement for Biomea as it looks to address unmet medical needs in diabetes treatment.
Read more →Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
Biomea Fusion reported its financial results for the year ending December 31, 2025, highlighting the initiation of two Phase II trials for icovamenib in type 2 diabetes and the completion of a 52-week follow-up from a previous trial. The company anticipates data readouts from multiple ongoing studies in 2026, while maintaining a cash runway into early 2027. Despite a net loss, the company is optimistic about its clinical advancements.
Read more →